CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to
detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify
patients benefiting from CLDN18.2 targeting treatment.